VANI Vivani Medical, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1266806 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-3.9%
TTM EPS YoY26.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-372.2%
ROA-89.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | $0 | $0 | $0 |
| R&D expense | $5.02M | $4.46M | $4.39M | $4.63M | $4.52M | $4.76M | $4.22M | $4.30M |
| SG&A expense | $2.51M | $2.42M | $2.43M | $2.18M | $2.21M | $2.70M | $2.34M | $2.16M |
| Operating income | -$7.53M | -$6.87M | -$6.82M | -$6.81M | -$6.72M | -$7.46M | -$6.56M | -$6.46M |
| Net income | -$7.25M | -$6.37M | -$6.78M | -$6.63M | -$6.53M | -$7.14M | -$6.30M | -$6.05M |
| EBITDA | -$7.40M | -$6.75M | -$6.69M | -$6.69M | -$6.62M | -$7.36M | -$6.46M | -$6.37M |
| EPS (basic) | -0.08 | -0.07 | -0.08 | — | -0.11 | -0.12 | -0.11 | — |
| EPS (diluted) | -0.08 | -0.07 | -0.08 | — | -0.11 | -0.12 | -0.11 | — |
| Weighted avg. shares (diluted) | 90.12M | 87.09M | 81.27M | — | 59.71M | 59.24M | 59.24M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.59M | $19.89M | $19.75M | $16.23M | $2.63M | $6.79M | $13.01M | $18.35M |
| Receivables | — | — | $12,000 | — | — | — | — | — |
| Current assets | $15.83M | $21.64M | $21.55M | $17.90M | $4.17M | $8.71M | $14.85M | $20.44M |
| PP&E, net | $2.76M | $2.85M | $2.75M | $2.88M | $2.73M | $1.58M | $1.61M | $1.69M |
| Total assets | $35.31M | $41.64M | $42.35M | $39.39M | $25.05M | $28.91M | $35.45M | $41.56M |
| Current liabilities | $6.58M | $6.66M | $6.78M | $6.60M | $6.83M | $6.72M | $6.20M | $5.99M |
| Total liabilities | $22.09M | $22.67M | $23.27M | $23.66M | $23.74M | $24.00M | $23.83M | $23.95M |
| Shareholders' equity | $13.22M | $18.97M | $19.09M | $15.73M | $1.31M | $4.91M | $11.62M | $17.61M |
| Shares outstanding | 76.43M | 89,410 | 84.65M | 76.43M | 61.51M | 59.24M | 59.24M | 59.23M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.39M | -$6.04M | -$6.20M | -$6.72M | -$6.35M | -$6.09M | -$5.16M | -$5.81M |
| Capital expenditure | $0 | $99,000 | $3,000 | $274,000 | $823,000 | $71,000 | $5,000 | $296,000 |
| Free cash flow | -$6.39M | -$6.13M | -$6.20M | -$6.99M | -$7.17M | -$6.16M | -$5.17M | -$6.11M |
| Investing cash flow | $0 | -$99,000 | -$3,000 | -$274,000 | -$823,000 | -$71,000 | -$5,000 | -$296,000 |
| Financing cash flow | $1.09M | $5.83M | $9.71M | $20.59M | $2.95M | -$95,000 | -$170,000 | $4.83M |
| Depreciation & amortization | $129,000 | $128,000 | $130,000 | $117,000 | $105,000 | $100,000 | $102,000 | $89,000 |
| Stock-based compensation | $378,000 | $313,000 | $312,000 | $467,000 | $276,000 | $391,000 | $350,000 | $402,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.